Novo Nordisk A/S $NVO Shares Bought by Vanguard Personalized Indexing Management LLC

Key Points

• Vanguard Personalized Indexing Management LLC increased its stake in Novo Nordisk A/S by 17.4%, acquiring a total of 149,916 shares worth approximately $10.35 million.
• A number of analysts upgraded Novo Nordisk's stock ratings recently, with two analysts giving it a "Strong Buy" rating and an average target price set at $77.50.
• During its latest quarter, Novo Nordisk reported $11.69 billion in revenue and a net margin of 35.60%, surpassing analysts' earnings expectations.

Vanguard Personalized Indexing Management LLC boosted its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 17.4% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 149,916 shares of the company's stock after buying an additional 22,191 shares during the quarter. Vanguard Personalized Indexing Management LLC's holdings in Novo Nordisk A/S were worth $10,349,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Concurrent Investment Advisors LLC raised its holdings in Novo Nordisk A/S by 35.5% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 59,441 shares of the company's stock valued at $4,103,000 after acquiring an additional 15,585 shares during the last quarter. Johnson Investment Counsel Inc. raised its holdings in Novo Nordisk A/S by 28.4% in the 2nd quarter. Johnson Investment Counsel Inc. now owns 20,379 shares of the company's stock valued at $1,407,000 after acquiring an additional 4,511 shares during the last quarter. Sivik Global Healthcare LLC raised its holdings in Novo Nordisk A/S by 42.9% in the 2nd quarter. Sivik Global Healthcare LLC now owns 100,000 shares of the company's stock valued at $6,902,000 after acquiring an additional 30,000 shares during the last quarter. Fifth Third Wealth Advisors LLC raised its holdings in Novo Nordisk A/S by 29.9% in the 2nd quarter. Fifth Third Wealth Advisors LLC now owns 5,428 shares of the company's stock valued at $375,000 after acquiring an additional 1,249 shares during the last quarter. Finally, Natural Investments LLC raised its holdings in Novo Nordisk A/S by 6.8% in the 2nd quarter. Natural Investments LLC now owns 19,454 shares of the company's stock valued at $1,342,000 after acquiring an additional 1,246 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently commented on NVO shares. Hsbc Global Res upgraded Novo Nordisk A/S from a "hold" rating to a "strong-buy" rating in a report on Wednesday, October 1st. Rothschild Redb upgraded Novo Nordisk A/S from a "hold" rating to a "strong-buy" rating in a report on Tuesday, September 16th. UBS Group downgraded Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a report on Tuesday, August 5th. BNP Paribas upgraded Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a report on Wednesday, August 13th. Finally, Rothschild & Co Redburn upgraded Novo Nordisk A/S from a "neutral" rating to a "buy" rating in a report on Tuesday, September 16th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Novo Nordisk A/S has an average rating of "Moderate Buy" and an average target price of $77.50.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $56.95 on Monday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. Novo Nordisk A/S has a one year low of $45.05 and a one year high of $120.56. The company's 50-day simple moving average is $55.44 and its 200-day simple moving average is $63.11. The stock has a market capitalization of $254.27 billion, a price-to-earnings ratio of 15.64, a PEG ratio of 2.58 and a beta of 0.68.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The business had revenue of $11.69 billion for the quarter, compared to analysts' expectations of $77.51 billion. Equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were paid a $0.4119 dividend. The ex-dividend date was Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S's dividend payout ratio (DPR) is presently 22.53%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.